Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
AVAILABLE
NCT03576690
R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
Sponsor: Regeneron Pharmaceuticals
View on ClinicalTrials.gov
Summary
Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).
Official title: Expanded Access Protocol for Emergency Use of REGN3470-3471-3479 for the Treatment of Ebola Virus Disease
Key Details
Gender
All
Age Range
Any - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-10-09
Healthy Volunteers
Not specified
Conditions
Interventions
BIOLOGICAL
REGN3470-3471-3479